Healthcare new lows: ArQule (NASDAQ:ARQL), OvaScience Inc. (NASDAQ:OVAS), Trevena Inc. (NASDAQ:TRVN), Egalet Corp (NASDAQ:EGLT)

Posted by on Apr 17, 2014

ArQule (NASDAQ:ARQL) Director Patrick Zenner bought 4,715 shares of the stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $2.12 per share, for a total transaction of $9,995.80. ArQule, Inc. (NASDAQ:ARQL) shares after opening at $1.76 moved to $1.77 on last trade day and at the end of the day closed at $1.71. Company price to sales ratio in past twelve months was calculated as 6.76 and price to cash ratio as 1.44. ArQule, Inc. (NASDAQ:ARQL) showed a negative weekly performance of -14.07%.

One stock that might be an intriguing choice for investors right now is OvaScience, Inc. (NASDAQ:OVAS). This is because this security in the Med-Biomed/Generic industry space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. OvaScience Inc. (NASDAQ:OVAS) shares fell -1.80% in last trading session and ended the day on $8.17. OVAS return on equity ratio is recorded as -57.00% and its return on assets is -53.90%. OvaScience Inc. (NASDAQ:OVAS) yearly performance is -17.47%.

On March 31, 2014, the Board of Directors of Trevena, Inc. (NASDAQ:TRVN) elected Robert Prachar as the Company’s Senior Vice President, Commercial and Corporate Strategy. Trevena Inc. (NASDAQ:TRVN) shares moved up 2.62% in last trading session and was closed at $5.10, while trading in range of $4.74 – $5.14. Trevena Inc. (NASDAQ:TRVN) year to date (YTD) performance is -21.54%.

Specialty pharmaceutical company, Egalet Corp (NASDAQ:EGLT), has announced positive results for Phase 1 study of its Egalet-001, an abuse deterrent oral morphine product that is being developed for the treatment of severe chronic pain. Egalet Corp (NASDAQ:EGLT) weekly performance is -19.17%. On last trading day company shares ended up $10.16. Egalet Corp (NASDAQ:EGLT) distance from 50-day simple moving average (SMA50) is -27.46%. Analysts mean target price for the company is $19.67.

Leave a Reply

Your email address will not be published. Required fields are marked *